Literature DB >> 32951825

Baeyer-Villiger monooxygenases: From protein engineering to biocatalytic applications.

Sandy Schmidt1, Uwe T Bornscheuer2.   

Abstract

Biocatalytic processes are well established for the synthesis of high-value fine chemicals, especially for chiral pharmaceutical intermediates, by using natural or engineered enzymes. In contrast, examples for the enzymatic synthesis of bulk chemicals are still rare. Especially for the synthesis of polymer precursors such as ɛ-caprolactone, that is still produced under harsh conditions by using peracetic acid, Baeyer-Villiger monooxygenases (BVMOs) represent promising alternative catalysts that can perform the reaction under mild conditions. However, industrial production of this bulk chemical using a biocatalyst such as a BVMO has not been achieved yet due to a number of reasons. In this book chapter, we are emphasizing the versatility of BVMOs and their catalyzed reactions, and address several examples where protein engineering was applied in order to overcome several limitations associated to the use of BVMOs. Finally, we highlight several examples of BVMO applications, either in single enzyme transformations, or BVMOs involved in cascade reactions. By mainly focusing on recent developments and achievements in the field, we outline different concepts that were developed in order to pave the way for an industrial application of BVMOs.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Baeyer-Villiger; Biocatalysis; Cascades; Cyclohexanone monooxygenase; Oxidation; Protein engineering

Year:  2020        PMID: 32951825     DOI: 10.1016/bs.enz.2020.05.007

Source DB:  PubMed          Journal:  Enzymes        ISSN: 1874-6047


  1 in total

1.  Mutations Increasing Cofactor Affinity, Improve Stability and Activity of a Baeyer-Villiger Monooxygenase.

Authors:  Hamid R Mansouri; Oriol Gracia Carmona; Julia Jodlbauer; Lorenz Schweiger; Michael J Fink; Erik Breslmayr; Christophe Laurent; Saima Feroz; Leticia C P Goncalves; Daniela V Rial; Marko D Mihovilovic; Andreas S Bommarius; Roland Ludwig; Chris Oostenbrink; Florian Rudroff
Journal:  ACS Catal       Date:  2022-09-13       Impact factor: 13.700

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.